Health Canada Drug Submission: NDS Process and Requirements

Health Canada Drug Submission: NDS Process and Requirements

Key Takeaways

Health Canada's Drug Review Organization

Health Canada's drug review function sits within the Health Products and Food Branch (HPFB), which contains the directorates responsible for pre-market review.

Key Directorates

TPD handles the majority of new drug submissions for pharmaceutical products. BRDD reviews biologics, including monoclonal antibodies, vaccines, and blood products. The distinction matters because each directorate has its own review divisions and slightly different internal processes.

The Office of Regulatory Operations (ORO) manages administrative functions including submission receipt, screening, and fee processing across directorates.

Regulatory Authority

Health Canada derives its authority from the Food and Drugs Act, with detailed requirements specified in the Food and Drug Regulations. The key regulatory sections for drug submissions are:

• Division 8 (C.08): New Drug requirements
• C.08.002: New Drug Submission requirements
• C.08.002.1: Abbreviated New Drug Submission requirements
• C.08.003: Submission content requirements
• C.08.004: Review, authorization, and Notice of Compliance provisions
• C.08.004.1: Data protection provisions for innovative drugs

Types of Drug Submissions in Canada

Health Canada accepts several submission types depending on the product and the regulatory strategy.

Primary Submission Types

When to File an NDS

An NDS is required when a drug has not previously been sold in Canada and when the submission relies on the sponsor's own clinical and non-clinical data rather than a comparison to a Canadian Reference Product. This includes:

• Novel active substances not previously authorized in Canada
• New combinations of previously approved substances
• Products where no suitable Canadian Reference Product exists
• Biologics seeking initial market authorization (filed as NDS to BRDD)

An ANDS is appropriate when the sponsor can demonstrate bioequivalence to an already-approved Canadian Reference Product and does not need to submit a full clinical data package.

NDS Content Requirements: The eCTD Format

Health Canada requires sponsors to follow its current electronic filing guidance when preparing an NDS. The management guidance states that paper documents are no longer accepted for drug submissions and applications and directs sponsors to the applicable eCTD or non-eCTD electronic-only filing instructions.

eCTD Module Structure for Health Canada

The eCTD follows the ICH CTD structure (Modules 1-5), with Module 1 containing Canada-specific administrative and regional information.

Module 1: Canadian Requirements

Module 1 for Health Canada submissions has a distinct structure compared to FDA or EMA Module 1. Key components include:

1.1 Forms and Administrative Information

• HC/SC Drug Submission Application Form (HC/SC 3011)
• Fee form and payment confirmation
• Attestation letters

1.2 Cover Letter

• Must clearly identify the submission type, drug name, active ingredient, and proposed indication
• Reference to any pre-submission correspondence or meetings

1.3 Product Monograph

• The Canadian equivalent of the US Prescribing Information (USPI) or EU SmPC
• Must follow the Health Canada Product Monograph template
• Bilingual requirements (English and French) apply for marketed products
• Includes Patient Medication Information (PMI) section

1.4 Labeling

• Inner and outer labels
• Must comply with C.01.004 labeling requirements
• Bilingual (English/French) as per the Official Languages Act

1.5 References (Right of Reference)

• Letters of Authorization if referencing another sponsor's data
• Cross-reference letters to Drug Master Files (DMFs) held at Health Canada

Submission Filing via the Common Electronic Submissions Gateway (CESG)

Health Canada receives electronic submissions through the Common Electronic Submissions Gateway (CESG) using the Regulatory Enrolment Process (REP). Sponsors filing in eCTD format should follow Health Canada's current eCTD preparation guidance, the Canadian Module 1 backbone requirements, and the live technical validation rules published by Health Canada.

The NDS Review Process: From Filing to NOC

The Health Canada NDS review process follows a structured sequence of stages, each with defined timelines and decision points.

Stage 1: Submission Receipt and Administrative Screening

When a submission arrives via CESG, the Office of Regulatory Operations (ORO) conducts an administrative screening:

• Verify that the correct forms are included and completed
• Confirm fee payment
• Check that the eCTD validates technically (XML backbone, PDF specifications)
• Assign a submission control number

If administrative requirements are not met, ORO issues a rejection letter and the submission is not accepted for screening.

Stage 2: Screening

Screening is the substantive review of whether the submission is sufficiently complete to proceed to full review. Health Canada conducts screening within 45 calendar days of the submission receipt date.

During screening, reviewers assess:

• Completeness: Are all required modules and sections populated?
• Quality of data: Is the CMC section adequate? Are clinical study reports included?
• Regulatory compliance: Does Module 1 contain required Canadian elements?
• Product Monograph: Is it present and in the correct format?

Screening outcomes:

A Screening Deficiency Notice (SDN) is not a rejection. The sponsor can address the deficiencies and resubmit the missing or corrected information within 45 calendar days. If the response is adequate, the submission proceeds to review. If the response is inadequate or not received within the timeframe, the submission is rejected.

Stage 3: Review

Once accepted for review, Health Canada conducts a multi-disciplinary assessment covering:

• Quality (CMC): Manufacturing, controls, stability, specifications
• Non-clinical: Pharmacology, toxicology
• Clinical: Efficacy and safety data
• Biostatistics: Statistical analysis verification
• Labeling: Product Monograph review

During review, Health Canada may issue clarification requests or a Notice of Deficiency (NOD) if additional information or data is needed. Under the current management guidance, a response to an NOD for an NDS is generally due within 90 calendar days unless another period is agreed with Health Canada.

Stage 4: Decision

At the conclusion of review, Health Canada issues one of the following decisions:

A Notice of Compliance (NOC) is the Canadian equivalent of an FDA approval letter. Upon issuance of an NOC, the drug is assigned a Drug Identification Number (DIN), which is required before the product can be sold in Canada.

Review Timelines and Performance Targets

Health Canada publishes performance targets for submission review through the Management of Drug Submissions and Applications (MDSA) policy. These targets vary by submission type and whether an expedited pathway is used.

Standard Review Timelines

These are calendar day targets. The review clock stops when a Notice of Deficiency is issued and resumes when the sponsor responds.

Expedited Review Timelines

These are Health Canada's published targets. Actual elapsed time can be longer if screening deficiencies, NODs, or other clock-stopping events occur.

Expedited Regulatory Pathways

Health Canada offers several mechanisms to accelerate review of drugs that address serious unmet medical needs.

Priority Review

Regulatory basis: Guidance for industry: Priority review of drug submissions

Priority review status must be requested before filing. Eligibility criteria include:

• The drug treats a serious, life-threatening, or severely debilitating disease or condition
• The drug provides significant increase in efficacy or significant decrease in risk compared to existing therapies
• OR the drug treats a disease for which no therapy currently exists in Canada

If granted, the sponsor should clearly identify the priority status in the cover letter and file the submission within 60 calendar days. The review target is reduced from 300 to 180 calendar days.

Notice of Compliance with Conditions (NOC/c)

Regulatory basis: Guidance Document: Notice of Compliance with Conditions (NOC/c)

NOC/c is a conditional authorization pathway for drugs that treat serious, life-threatening, or severely debilitating diseases where:

• Existing therapies are inadequate or unavailable
• The drug shows promising clinical benefit based on surrogate endpoints or limited clinical data
• The sponsor commits to post-market confirmatory studies

Upon NOC/c issuance, the Product Monograph must include a statement that the drug was authorized under the NOC/c policy and describe the post-market commitments.

If the sponsor fails to complete post-market commitments or confirmatory data does not support the initial benefit-risk assessment, Health Canada may suspend or cancel the NOC/c.

If the sponsor wants advance consideration under the NOC/c policy before filing, Health Canada instructs sponsors to request a pre-submission meeting with the appropriate review area. If the submission is considered suitable for advance consideration, it should be filed within 60 calendar days.

Pre-Submission Activities

Pre-Submission Meetings

Health Canada offers pre-submission or pre-application meetings to discuss questions before filing an NDS, SNDS, CTA, priority review request, or other regulated activity. These meetings can help clarify the planned evidence package, filing pathway, and any Canada-specific administrative requirements.

Clinical Trial Application (CTA)

Before conducting clinical trials in Canada, sponsors must file a Clinical Trial Application (CTA) under Division 5 of the Food and Drug Regulations (C.05.005). If Health Canada does not issue an objection within 30 days, the trial may proceed.

CTAs may be filed in eCTD or non-eCTD format, depending on the current Health Canada CTA filing instructions. A CTA includes, among other things:

• Clinical trial protocol
• Investigator's Brochure
• Informed consent form
• CMC information for the investigational product
• Available non-clinical and clinical safety data

Health Canada may issue a Not Satisfactory Notice (NSN) within 30 days if the CTA raises safety concerns, which prevents the trial from proceeding.

Drug Identification Number (DIN) and Post-Authorization

DIN Assignment

Upon issuance of an NOC, Health Canada assigns a Drug Identification Number (DIN) to the product. The DIN is an 8-digit numerical code that uniquely identifies the drug product (active ingredient, strength, dosage form, route of administration, and manufacturer).

The DIN must appear on all drug labels and is required before the product can be sold in Canada. DIN information is publicly available in the Drug Product Database (DPD) maintained by Health Canada.

Post-Market Obligations

After receiving an NOC, the sponsor has ongoing obligations:

• Annual Drug Notification (ADN): Confirm the drug is still marketed and that information remains accurate
• Adverse Reaction Reporting: Report serious adverse reactions within 15 calendar days per C.01.017
• Periodic safety reporting: Submit post-market safety information when required by applicable law, terms and conditions, or Health Canada requests
• Post-market commitments: Complete any studies required under NOC/c or as conditions of authorization
• SNDS for changes: File supplements for changes to formulation, manufacturing, indications, or labeling

Drug Product Database (DPD)

All drugs authorized for sale in Canada are listed in the Drug Product Database (DPD), which is publicly searchable at https://health-products.canada.ca/dpd-bdpp/. The DPD contains information on the active ingredient, company, DIN, dosage form, route of administration, and product status.

Common Reasons for Screening Rejection

Understanding common screening issues can prevent costly delays. Health Canada's screening guidance shows that typical problems include:

Health Canada publishes a screening checklist in its "Guidance Document: Management of Drug Submissions and Applications" (MDSA) that sponsors should reference before filing.

Fees for Drug Submissions

Health Canada charges review fees under the Fees in Respect of Drugs and Medical Devices Order. Because the fee schedule is updated, sponsors should verify the current published fee tables and any remission policies on Health Canada's official fees page before filing.

Key Regulatory References

• Food and Drugs Act
• Food and Drug Regulations
• Guidance on management of drug submissions and applications: pre-application and filing
• Guidance on management of drug submissions and applications: processing and screening
• Guidance on management of drug submissions and applications: review
• Filing submissions electronically
• Guidance for industry: Priority review of drug submissions
• Guidance Document: Notice of Compliance with Conditions (NOC/c)
• Fees for drugs and medical devices

References

This guide reflects Health Canada's drug submission requirements as of early 2026. Regulatory requirements are subject to change. Always verify current requirements against Health Canada's official guidance documents before filing.